- Navigating Your Midlife Crisis: Embracing New Possibilities
- City Raccoons Showing Signs of Domestication
- Mapping the Exposome: Science Broadens Focus to Environmental Disease Triggers
- One Week Less on Social Media Linked to Better Mental Health
- Your Brain Changes in Stages as You Age, Study Finds
- Some Suicide Victims Show No Typical Warning Signs, Study Finds
- ByHeart Formula Faces Lawsuits After Babies Sickened With Botulism
- Switch to Vegan Diet Could Cut Your Greenhouse Gas Emissions in Half
- Regular Bedtime Does Wonders for Blood Pressure
- Dining Alone Could Mean Worse Nutrition for Seniors
Health Highlights, April 23, 2021
Pfizer and Moderna Vaccines Effective Against New NYC Variant, Two Studies Show
The Pfizer-BioNTech and Moderna COVID-19 vaccines protect against serious illness and death from the coronavirus variant first identified in New York city, two new studies show.
The B.1.526 variant was first detected in November and accounted for nearly half of cases diagnosed in the city as of April 13. City officials have said the variant may be more contagious and may be able to avoid the immune response triggered by the vaccines, The New York Times reported.
But the two independent studies found that antibodies stimulated by the Pfizer-BioNTech and Moderna COVID-19 vaccines are only slightly less effective against the variant than the original form of the novel coronavirus.
The findings — which haven’t been peer-reviewed — are based on laboratory experiments with blood samples from small numbers of vaccinated people, the Times reported.
The studies add to growing evidence that the two vaccines protect against all coronavirus variants identified so far.
“We’re not seeing big differences,” Michel Nussenzweig, a Rockefeller University immunologist who was a researcher on one of the studies, told the Times.
The bottom line? “Get vaccinated,” he added.
“The take-home message is that the vaccines are going to work against the New York variant and the South African variant and the U.K. variant,” Nathan Landau, a virologist at N.Y.U.’s Grossman School of Medicine who led the other study, told the Times.
Copyright © 2025 HealthDay. All rights reserved.










